Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-A12 or Ramucirumab with Mitoxantrone and Prednisone in Metastatic AIPC
NCT00683475Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2008
- Primary completion
- Sep 2011
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cixutumumab, ramucirumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Eli Lilly and Company. Started Aug 2008; status: completed.
02
Drugs
cixutumumabramucirumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00683475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00683475.